MX2020014101A - Anticuerpo que induce tolerancia inmunitaria, linfocito inducido, y agente de terapia celular/metodo terapeutico que usa linfocitos inducidos. - Google Patents

Anticuerpo que induce tolerancia inmunitaria, linfocito inducido, y agente de terapia celular/metodo terapeutico que usa linfocitos inducidos.

Info

Publication number
MX2020014101A
MX2020014101A MX2020014101A MX2020014101A MX2020014101A MX 2020014101 A MX2020014101 A MX 2020014101A MX 2020014101 A MX2020014101 A MX 2020014101A MX 2020014101 A MX2020014101 A MX 2020014101A MX 2020014101 A MX2020014101 A MX 2020014101A
Authority
MX
Mexico
Prior art keywords
induced lymphocyte
induced
therapeutic method
cell therapy
therapy agent
Prior art date
Application number
MX2020014101A
Other languages
English (en)
Inventor
Ryu Maeda
Masayuki Kawakami
Koichiro Uchida
Kazuyoshi Takeda
Ko Okumura
Original Assignee
Junten Bio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Junten Bio Co Ltd filed Critical Junten Bio Co Ltd
Publication of MX2020014101A publication Critical patent/MX2020014101A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción proporciona un anticuerpo para inducir tolerancia inmunitaria, un linfocito inducido y un método terapéutico de agente de terapia celular que utiliza el linfocito inducido; específicamente, la presente descripción proporciona un anticuerpo que inhibe la interacción entre CD80 y/o CD86 expresado en la superficie de una determinada célula y CD28 expresado en la superficie de otra célula, y sustancialmente no induce citocinas inducidas por activación inmune; en una modalidad específica, la porción Fc del anticuerpo no produce sustancialmente las citosinas inducidas por activación inmune.
MX2020014101A 2018-06-22 2019-06-21 Anticuerpo que induce tolerancia inmunitaria, linfocito inducido, y agente de terapia celular/metodo terapeutico que usa linfocitos inducidos. MX2020014101A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018118996 2018-06-22
PCT/JP2019/024752 WO2019245037A1 (ja) 2018-06-22 2019-06-21 免疫寛容を誘導する抗体、誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤治療法

Publications (1)

Publication Number Publication Date
MX2020014101A true MX2020014101A (es) 2021-05-27

Family

ID=68984092

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020014101A MX2020014101A (es) 2018-06-22 2019-06-21 Anticuerpo que induce tolerancia inmunitaria, linfocito inducido, y agente de terapia celular/metodo terapeutico que usa linfocitos inducidos.

Country Status (11)

Country Link
US (1) US20210269529A1 (es)
EP (1) EP3845652A4 (es)
JP (2) JP6999809B2 (es)
KR (1) KR20210025062A (es)
CN (1) CN112585273A (es)
AU (1) AU2019288635A1 (es)
BR (1) BR112020025504A2 (es)
CA (1) CA3104783A1 (es)
IL (1) IL279653A (es)
MX (1) MX2020014101A (es)
WO (1) WO2019245037A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023153388A1 (ja) * 2022-02-08 2023-08-17 学校法人順天堂 他家移植方法及び拒絶反応抑制方法
WO2023190942A1 (ja) * 2022-03-31 2023-10-05 学校法人順天堂 誘導型抑制性ｔ細胞製剤の品質を評価する方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU6290090A (en) 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
IL133070A0 (en) 1997-06-11 2001-03-19 Us Navy Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
AU2001264747A1 (en) * 2000-05-22 2001-12-03 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and thehuman b7.1 and b7.2 co-stimulatory antigens
CA2516832A1 (en) * 2003-02-27 2004-09-10 Theravision Gmbh A molecule which binds cd80 and cd86
JP2007131598A (ja) 2005-11-14 2007-05-31 Kurosu Biotech:Kk 腎移植拒絶反応抑制剤
CN102481367B (zh) * 2009-07-06 2015-04-29 弗·哈夫曼-拉罗切有限公司 结合地高辛配基的双特异性抗体
NZ710730A (en) 2013-03-15 2021-07-30 Viropharma Biologics Llc C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency
JP6584387B2 (ja) * 2013-05-17 2019-10-02 株式会社Ｊｕｎｔｅｎ Ｂｉｏ 調節性ｔ細胞及びその使用
EP2870972A1 (en) 2013-11-06 2015-05-13 Paul Scherrer Institut Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment
JP2018190031A (ja) 2017-04-28 2018-11-29 キヤノン株式会社 管理装置、方法及びプログラム

Also Published As

Publication number Publication date
IL279653A (en) 2021-03-01
JP2022028075A (ja) 2022-02-14
CN112585273A (zh) 2021-03-30
US20210269529A1 (en) 2021-09-02
EP3845652A4 (en) 2022-04-13
CA3104783A1 (en) 2019-12-26
TW202016312A (zh) 2020-05-01
JP6999809B2 (ja) 2022-02-04
KR20210025062A (ko) 2021-03-08
WO2019245037A1 (ja) 2019-12-26
JPWO2019245037A1 (ja) 2021-03-25
BR112020025504A2 (pt) 2021-03-16
EP3845652A1 (en) 2021-07-07
AU2019288635A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
MX2019011858A (es) Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
MX2020010379A (es) Sistemas y metodos de procesamiento.
PH12018501453A1 (en) Chimeric proteins and methods of immuno therapy
EP3752973A4 (en) SYSTEM AND METHOD FOR GENERATING ASPECT EXTENDED EXPLANATABLE DESCRIPTION-BASED RECOMMENDATIONS
MX2017016927A (es) Métodos y aparato para inducir un modo de onda no fundamental en un medio de transmisión.
WO2018128695A3 (en) Gas flow in three-dimensional printing
MX2022008338A (es) Inmunoterapia antitumoral combinada.
PH12020551437A1 (en) Methods for treating hpv-associated diseases
SG11201900171QA (en) Antibody for anti-claudin 18a2 and use thereof
MX2017010254A (es) Percepciones en un sistema haptico.
GT201600171A (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblástica aguda
MX2018015352A (es) Subtipos de receptores y compuestos retinoides y rexinoides de funcion selectiva combinados con moduladores inmunitarios para inmunoterapia contra el cancer.
WO2018218085A3 (en) THREE-DIMENSIONAL PRINTED ORGANS, DEVICES, AND ARRAYS
MX2018013762A (es) Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso.
MX2019010397A (es) Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
AU2018289493A1 (en) Methods for modulating regulatory T cells, regulatory B cells, and immune responses using modulators of the APRIL-TACI interaction
SG11201805655VA (en) Method and device for bonding substrates
WO2017117520A8 (en) A method, system and apparatus using forward-secure cryptography for passcode verification
AU2015255979B2 (en) Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses
MX2020014101A (es) Anticuerpo que induce tolerancia inmunitaria, linfocito inducido, y agente de terapia celular/metodo terapeutico que usa linfocitos inducidos.
EP3528158A3 (en) Method and apparatus for selective combined authentication
SG11201808444VA (en) Method and device for bonding two substrates
EP4346129A3 (en) Noise reduction method and system
MX2019013656A (es) Metodo y aparato de laminacion de material no tejido elastico.
CO2021011034A2 (es) Métodos para tratar el mieloma múltiple